These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15507504)

  • 1. The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.
    Prescott WA; Streetman DA; Streetman DS
    Ann Pharmacother; 2004 Dec; 38(12):2105-14. PubMed ID: 15507504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins.
    Wheeler DC
    J Nephrol; 2001; 14 Suppl 4():S70-5. PubMed ID: 11798150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preprocedural statin therapy in percutaneous coronary intervention.
    Cahoon WD; Crouch MA
    Ann Pharmacother; 2007 Oct; 41(10):1687-93. PubMed ID: 17712042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosuvastatin in the management of hyperlipidemia.
    Cheng JW
    Clin Ther; 2004 Sep; 26(9):1368-87. PubMed ID: 15531000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pitavastatin: a new HMG-CoA reductase inhibitor.
    Wensel TM; Waldrop BA; Wensel B
    Ann Pharmacother; 2010 Mar; 44(3):507-14. PubMed ID: 20179258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerivastatin.
    Cheng-Lai A
    Heart Dis; 2000; 2(1):93-9. PubMed ID: 11728245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients.
    de Denus S; Al-Jazairi A; Loh E; Jessup M; Stanek EJ; Spinler SA
    Ann Pharmacother; 2004; 38(7-8):1136-41. PubMed ID: 15150383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cholesterol and statins in Alzheimer's disease.
    Miller LJ; Chacko R
    Ann Pharmacother; 2004 Jan; 38(1):91-8. PubMed ID: 14742802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration.
    Plakogiannis R; Cohen H
    Ann Pharmacother; 2007 Jan; 41(1):106-10. PubMed ID: 17200427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary event secondary prevention with statins irrespective of LDL-cholesterol.
    Kerst LL; Mauro VF
    Ann Pharmacother; 2004 Jun; 38(6):1060-4. PubMed ID: 15121997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
    Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
    Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins and progression of calcified aortic stenosis.
    Chua D; Kalb K
    Ann Pharmacother; 2006 Dec; 40(12):2195-9. PubMed ID: 17132803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should hyperlipidemia in children with the nephrotic syndrome be treated?
    Querfeld U
    Pediatr Nephrol; 1999 Jan; 13(1):77-84. PubMed ID: 10100296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations for supplementing with coenzyme Q10 during statin therapy.
    Levy HB; Kohlhaas HK
    Ann Pharmacother; 2006 Feb; 40(2):290-4. PubMed ID: 16449543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein.
    Backes JM; Gibson CA
    Ann Pharmacother; 2005 Mar; 39(3):523-6. PubMed ID: 15671087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.